BACKGROUND: Deep brain stimulation electrode placement with interventional magnetic resonance imaging (MRI) has previously been reported using a commercially available skull-mounted aiming device (Medtronic Nexframe MR) and native MRI scanner software. This first-generation method has technical limitations that are inherent to the hardware and software used. A novel system (SurgiVision ClearPoint) consisting of an aiming device (SMARTFrame) and software has been developed specifically for interventional MRI, including deep brain stimulation. OBJECTIVE: To report a series of phantom and cadaver tests performed to determine the capability, preliminary accuracy, and workflow of the system. METHODS: Eighteen experiments using a water phantom were used to determine the predictive accuracy of the software. Sixteen experiments using a gelatin-filled skull phantom were used to determine targeting accuracy of the aiming device. Six procedures in 3 cadaver heads were performed to compare the workflow and accuracy of ClearPoint with Nexframe MR. RESULTS: Software prediction experiments showed an average error of 0.9 ± 0.5 mm in magnitude in pitch and roll (mean pitch error, -0.2 ± 0.7 mm; mean roll error, 0.2 ± 0.7 mm) and an average error of 0.7 ± 0.3 mm in X-Y translation with a slight anterior (0.5 ± 0.3 mm) and lateral (0.4 ± 0.3 mm) bias. Targeting accuracy experiments showed an average radial error of 0.5 ± 0.3 mm. Cadaver experiments showed a radial error of 0.2 ± 0.1 mm with the ClearPoint system (average procedure time, 88 ± 14 minutes) vs 0.6 ± 0.2 mm with the Nexframe MR (average procedure time, 92 ± 12 minutes). CONCLUSION: This novel system provides the submillimetric accuracy required for stereotactic interventions, including deep brain stimulation placement. It also overcomes technical limitations inherent in the first-generation interventional MRI system.
BACKGROUND: Deep brain stimulation electrode placement with interventional magnetic resonance imaging (MRI) has previously been reported using a commercially available skull-mounted aiming device (Medtronic Nexframe MR) and native MRI scanner software. This first-generation method has technical limitations that are inherent to the hardware and software used. A novel system (SurgiVision ClearPoint) consisting of an aiming device (SMARTFrame) and software has been developed specifically for interventional MRI, including deep brain stimulation. OBJECTIVE: To report a series of phantom and cadaver tests performed to determine the capability, preliminary accuracy, and workflow of the system. METHODS: Eighteen experiments using a water phantom were used to determine the predictive accuracy of the software. Sixteen experiments using a gelatin-filled skull phantom were used to determine targeting accuracy of the aiming device. Six procedures in 3 cadaver heads were performed to compare the workflow and accuracy of ClearPoint with Nexframe MR. RESULTS: Software prediction experiments showed an average error of 0.9 ± 0.5 mm in magnitude in pitch and roll (mean pitch error, -0.2 ± 0.7 mm; mean roll error, 0.2 ± 0.7 mm) and an average error of 0.7 ± 0.3 mm in X-Y translation with a slight anterior (0.5 ± 0.3 mm) and lateral (0.4 ± 0.3 mm) bias. Targeting accuracy experiments showed an average radial error of 0.5 ± 0.3 mm. Cadaver experiments showed a radial error of 0.2 ± 0.1 mm with the ClearPoint system (average procedure time, 88 ± 14 minutes) vs 0.6 ± 0.2 mm with the Nexframe MR (average procedure time, 92 ± 12 minutes). CONCLUSION: This novel system provides the submillimetric accuracy required for stereotactic interventions, including deep brain stimulation placement. It also overcomes technical limitations inherent in the first-generation interventional MRI system.
Authors: M I Miga; D W Roberts; A Hartov; S Eisner; J Lemery; F E Kennedy; K D Paulsen Journal: Stereotact Funct Neurosurg Date: 1999 Impact factor: 1.875
Authors: A A F De Salles; L Frighetto; E Behnke; S Sinha; L Tseng; R Torres; M Lee; C Cabatan-Awang; R Frysinger Journal: Minim Invasive Neurosurg Date: 2004-10
Authors: Timothy J Carter; Maxime Sermesant; David M Cash; Dean C Barratt; Christine Tanner; David J Hawkes Journal: Med Eng Phys Date: 2005-11-03 Impact factor: 2.242
Authors: Alastair J Martin; Paul S Larson; Jill L Ostrem; W Keith Sootsman; Pekka Talke; Oliver M Weber; Nadja Levesque; Jeffrey Myers; Philip A Starr Journal: Magn Reson Med Date: 2005-11 Impact factor: 4.668
Authors: Kathryn L Holloway; Steven E Gaede; Philip A Starr; Joshua M Rosenow; Viswanathan Ramakrishnan; Jaimie M Henderson Journal: J Neurosurg Date: 2005-09 Impact factor: 5.115
Authors: C W Christine; P A Starr; P S Larson; J L Eberling; W J Jagust; R A Hawkins; H F VanBrocklin; J F Wright; K S Bankiewicz; M J Aminoff Journal: Neurology Date: 2009-10-14 Impact factor: 9.910
Authors: Michael G Kaplitt; Andrew Feigin; Chengke Tang; Helen L Fitzsimons; Paul Mattis; Patricia A Lawlor; Ross J Bland; Deborah Young; Kristin Strybing; David Eidelberg; Matthew J During Journal: Lancet Date: 2007-06-23 Impact factor: 79.321
Authors: Niravkumar A Patel; Christopher J Nycz; Paulo A Carvalho; Katie Y Gandomi; Radian Gondokaryono; Gang Li; Tamas Heffter; Everette Clif Burdette; Julie G Pilitsis; Gregory S Fischer Journal: IEEE Trans Biomed Eng Date: 2020-02-17 Impact factor: 4.538
Authors: Marc C Mabray; Sanjit Datta; Prasheel V Lillaney; Teri Moore; Sonja Gehrisch; Jason F Talbott; Michael R Levitt; Basavaraj V Ghodke; Paul S Larson; Daniel L Cooke Journal: J Neurointerv Surg Date: 2015-06-05 Impact factor: 5.836
Authors: Seunggu J Han; Krystof Bankiewicz; Nicholas A Butowski; Paul S Larson; Manish K Aghi Journal: Expert Rev Neurother Date: 2016-04-20 Impact factor: 4.618
Authors: Jason J Lamanna; Lindsey N Urquia; Carl V Hurtig; Juanmarco Gutierrez; Cody Anderson; Pete Piferi; Thais Federici; John N Oshinski; Nicholas M Boulis Journal: Stereotact Funct Neurosurg Date: 2017-01-28 Impact factor: 1.875
Authors: Roy G Torcuator; M Maher Hulou; Vamsidhar Chavakula; Ferenc A Jolesz; Alexandra J Golby Journal: J Clin Neurosci Date: 2015-11-16 Impact factor: 1.961